Related references
Note: Only part of the references are listed.Gene Expression Profiling and Response Signatures Associated With Differential Responses to Infliximab Treatment in Ulcerative Colitis
Gary Toedter et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients
Lydia R. Coulthard et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Genome-Wide Association Study of Genetic Predictors of Anti-Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations With Polymorphisms at Seven Loci
Darren Plant et al.
ARTHRITIS AND RHEUMATISM (2011)
Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease
Laurent Peyrin-Biroulet et al.
GUT (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
Matthias Juergens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
Rachael J. L. Tan et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways
Catherine Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis
B. Stuhlmueller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Genome Wide Association (GWA) Predictors of Anti-TNFα Therapeutic Responsiveness in Pediatric Inflammatory Bowel Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2010)
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
Eli A. Stahl et al.
NATURE GENETICS (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke et al.
NATURE GENETICS (2010)
Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study
Marian Suarez-Gestal et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
C. Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
I. Arijs et al.
GUT (2009)
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk
Soumya Raychaudhuri et al.
NATURE GENETICS (2009)
An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid Arthritis
Antonio Julia et al.
PLOS ONE (2009)
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients
John D. Bowes et al.
PHARMACOGENETICS AND GENOMICS (2009)
TNF-α-308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis
D. D. O'Rielly et al.
PHARMACOGENOMICS JOURNAL (2009)
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Wolfgang Hueber et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at-308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor
Hubert Marotte et al.
ARTHRITIS AND RHEUMATISM (2008)
Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions
Robert M. Plenge et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis
James R. Maxwell et al.
HUMAN MOLECULAR GENETICS (2008)
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis
Chunyu Liu et al.
MOLECULAR MEDICINE (2008)
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Benjamin L. Ebert et al.
PLOS MEDICINE (2008)
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis
C. Miceli-Richard et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Influence of-308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis
Sandrine Guis et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M. Svenson et al.
RHEUMATOLOGY (2007)
Variation in TCF7L2 influences therapeutic response to sulfonylureas -: A GoDARTs study
Ewan R. Pearson et al.
DIABETES (2007)
Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis
G. Morozzi et al.
CLINICAL RHEUMATOLOGY (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis
Marieke J. H. Coenen et al.
PHARMACOGENOMICS (2007)
Combined tumour necrosis factor-α and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-α therapy and explain controversies of studies based on a single polymorphism
A. Chatzikyriakidou et al.
RHEUMATOLOGY (2007)
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
Tibor Hlavaty et al.
INFLAMMATORY BOWEL DISEASES (2007)
High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor a inhibitors in rheumatoid arthritis
Francesca Bobbio-Pallavicini et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis
Alf Kastbom et al.
ARTHRITIS AND RHEUMATISM (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF alpha-blockers in rheumatoid arthritis and spondyloarthritis patients
M. Seitz et al.
RHEUMATOLOGY (2007)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response
Ma-Li Wong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction
J Zwerina et al.
ARTHRITIS AND RHEUMATISM (2006)
Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis
Devesh Mewar et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Tumour necrosis factor (TNF)alpha-308 G/G promoter polymorphism and TNF alpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis
M. Cuchacovich et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2006)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents
Z Tutuncu et al.
ARTHRITIS AND RHEUMATISM (2005)
Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
L Bodin et al.
BLOOD (2005)
Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis
A Ranganathan
PHARMACOGENOMICS (2005)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Polymorphism at position-308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics
JE Fonseca et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis
H Schotte et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
TNF pathophysiology in murine models of chronic inflammation and autoimmunity
G Kollias
SEMINARS IN ARTHRITIS AND RHEUMATISM (2005)
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Elena Urcelay et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients
A Martinez et al.
ARTHRITIS AND RHEUMATISM (2004)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter
L Baseggio et al.
EUROPEAN JOURNAL OF IMMUNOGENETICS (2004)
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
M Feldmann et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2004)
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
C Alessandri et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept
LA Criswell et al.
ARTHRITIS AND RHEUMATISM (2004)
Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab
M Pierik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Tumour necrosis factor-α (TNF-α) levels and influence of 2308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis
M Cuchacovich et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2004)
Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis
A Balog et al.
PATHOBIOLOGY (2004)
Polymorphism at position-308 of the tumor necrosis factor a gene influences outcome of infliximab therapy in rheumatoid arthritis
B Mugnier et al.
ARTHRITIS AND RHEUMATISM (2003)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis
L Padyukov et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
MA Gardam et al.
LANCET INFECTIOUS DISEASES (2003)
Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept
M Crnkic et al.
ARTHRITIS RESEARCH & THERAPY (2003)
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene:: an analysis in 534 patients from two multicenter, prospective GCP-level trials
S Mascheretti et al.
PHARMACOGENETICS (2002)
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism
E Louis et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2002)
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
KD Taylor et al.
GASTROENTEROLOGY (2001)
Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
